Share This Page
Drug Price Trends for NDC 67877-0704
✉ Email this page to a colleague
Average Pharmacy Cost for 67877-0704
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DROXIDOPA 100 MG CAPSULE | 67877-0704-90 | 0.64272 | EACH | 2026-03-18 |
| DROXIDOPA 100 MG CAPSULE | 67877-0704-90 | 0.67350 | EACH | 2026-02-18 |
| DROXIDOPA 100 MG CAPSULE | 67877-0704-90 | 0.72301 | EACH | 2026-01-21 |
| DROXIDOPA 100 MG CAPSULE | 67877-0704-90 | 0.78385 | EACH | 2025-12-17 |
| DROXIDOPA 100 MG CAPSULE | 67877-0704-90 | 0.84042 | EACH | 2025-11-19 |
| DROXIDOPA 100 MG CAPSULE | 67877-0704-90 | 0.89134 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 67877-0704
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 67877-0704
Executive Summary
NDC 67877-0704, an approved therapeutic agent, faces a dynamic market environment characterized by patent exclusivity, evolving treatment paradigms, and potential generic competition. Current market penetration is driven by its efficacy in [briefly mention indication], with a projected compound annual growth rate (CAGR) of [X]% over the next five years. Price projections are influenced by factors including manufacturing costs, clinical utility, payer reimbursements, and competitive landscape. Analysis indicates a sustained premium pricing strategy for the branded product during its exclusivity period, followed by a significant price reduction upon market entry of biosimilars or generics.
What is the Current Market Landscape for NDC 67877-0704?
The market for NDC 67877-0704 is currently defined by its status as a novel therapeutic agent with established clinical utility in treating [specific indication]. Approved by the [Regulatory Body, e.g., FDA] on [Date of Approval], the drug has achieved a market share of approximately [X]% within its primary indication.
Key market drivers include:
- Clinical Efficacy: Demonstrated superiority or comparable efficacy to existing treatments in [specific clinical trial outcome, e.g., reducing disease progression by Y%].
- Patient Population: A target patient population estimated at [Number] individuals in [Geographic Region, e.g., the United States].
- Reimbursement Policies: Favorable reimbursement from major payers like [Payer Name 1] and [Payer Name 2], covering [X]% of the treatment cost for eligible patients.
- Physician Adoption: Growing prescriber confidence, evidenced by a [X]% increase in prescriptions over the past [Time Period, e.g., 12 months].
Market challenges include:
- Cost of Therapy: The current wholesale acquisition cost (WAC) is $[X] per [Unit, e.g., vial, month's supply], posing a barrier for some patient segments and healthcare systems.
- Competition: While direct branded competition is limited, alternative therapeutic classes, such as [mention competing drug classes or modalities], represent indirect competition.
- Adverse Event Profile: [Briefly mention any notable side effects or safety concerns that may impact adoption].
What is the Patent Protection Status and Exclusivity Timeline for NDC 67877-0704?
The patent landscape for NDC 67877-0704 is a critical determinant of its market exclusivity and future revenue potential. The drug's core patent family, encompassing its active pharmaceutical ingredient (API) and key manufacturing processes, is currently protected.
- Composition of Matter Patent: U.S. Patent No. [Patent Number] is set to expire on [Expiration Date]. This patent provides the broadest protection for the molecule itself.
- Method of Use Patents: Additional patents covering specific therapeutic applications, such as U.S. Patent No. [Patent Number] (expiring [Date]) and U.S. Patent No. [Patent Number] (expiring [Date]), further safeguard market exclusivity.
- Exclusivity Expirations:
- New Chemical Entity (NCE) exclusivity: [Date]
- Orphan Drug Exclusivity (if applicable): [Date]
- Any other relevant regulatory exclusivities: [Date]
Analysis of the patent portfolio indicates a clear window of market exclusivity for the innovator product until at least [Latest Key Patent Expiration Date]. Post-expiration, the market will be susceptible to generic or biosimilar entry, depending on the drug's modality.
What are the Projected Market Growth and Revenue Forecasts for NDC 67877-0704?
The market for NDC 67877-0704 is projected to experience sustained growth driven by increasing diagnosis rates, expanding indications (if applicable), and improved patient access.
Market Size Projections:
| Year | Estimated Market Size (USD Billions) |
|---|---|
| 2024 | [X.XX] |
| 2025 | [X.XX] |
| 2026 | [X.XX] |
| 2027 | [X.XX] |
| 2028 | [X.XX] |
This forecast is based on a CAGR of approximately [X]% from 2024 to 2028.
Revenue Forecasts (Innovator Product):
| Year | Projected Net Revenue (USD Billions) |
|---|---|
| 2024 | [X.XX] |
| 2025 | [X.XX] |
| 2026 | [X.XX] |
| 2027 | [X.XX] |
| 2028 | [X.XX] |
These projections assume continued market penetration and stable pricing until the primary patent expirations. Factors that could impact these forecasts include:
- Emergence of new therapeutic alternatives.
- Changes in payer formulary placement or prior authorization requirements.
- Faster-than-anticipated generic or biosimilar market entry.
What are the Key Factors Influencing Pricing for NDC 67877-0704?
Pricing for NDC 67877-0704 is influenced by a confluence of economic, clinical, and regulatory factors.
- Manufacturing Costs: The cost of goods sold (COGS) for NDC 67877-0704 is estimated at $[X] per [Unit]. This includes API synthesis, formulation, quality control, and packaging.
- Clinical Value and Unmet Needs: The drug addresses significant unmet needs in [specific indication], offering a [quantifiable clinical benefit]. This high clinical utility supports premium pricing.
- Payer Negotiations and Reimbursement: Reimbursement rates from major insurers significantly influence net revenue. Current average reimbursement per [Unit] is approximately $[X].
- Competitive Landscape: While direct competition is limited, the pricing of alternative therapies in the broader therapeutic category sets a ceiling for acceptable price increases.
- Post-Exclusivity Dynamics: The introduction of generics or biosimilars will exert downward pressure on pricing.
Current Pricing Structure:
- Wholesale Acquisition Cost (WAC): $[X] per [Unit]
- Average Wholesale Price (AWP): $[X] per [Unit]
- Estimated Net Price (post-rebates and discounts): $[X] per [Unit]
What are the Price Projections for NDC 67877-0704 Post-Patent Expiration?
The expiration of key patents for NDC 67877-0704 will trigger a significant shift in market dynamics, leading to substantial price erosion.
Projected Price Trends Post-Exclusivity:
| Time Period | Projected Price Change | Notes |
|---|---|---|
| 0-6 Months Post-Expiration | -40% to -60% | Initial entry of first-to-file generics or biosimilars, leading to rapid price reductions. |
| 6-24 Months Post-Expiration | -60% to -80% | Increased competition from multiple generic/biosimilar manufacturers drives prices lower. |
| 24+ Months Post-Expiration | -75% to -85% | Market stabilizes with mature generic/biosimilar penetration, with prices approaching manufacturing costs. |
Factors influencing post-expiration pricing:
- Number of Generic/Biosimilar Entrants: More entrants accelerate price declines.
- Pricing Strategies of Generic/Biosimilar Manufacturers: Aggressive pricing by early entrants.
- Payer Preferred Status: Payers may negotiate exclusive contracts with specific generic/biosimilar manufacturers.
- Manufacturing Efficiency of Generics/Biosimilars: Lower production costs for competitors.
The innovator product's price will likely be reduced to maintain a competitive edge against generics, but its market share will diminish considerably.
What are the Potential Risks and Opportunities in the Market for NDC 67877-0704?
Risks:
- Early Generic/Biosimilar Entry: Legal challenges or expedited FDA approvals for generics/biosimilars could shorten the exclusivity period.
- Clinical Trial Failures for New Indications: If ongoing or planned trials for expanded indications fail, future growth potential will be limited.
- Emergence of Superior Alternatives: Development of novel therapies with demonstrably better efficacy or safety profiles could displace NDC 67877-0704.
- Reimbursement Pressures: Increased scrutiny from payers on drug costs could lead to tighter formulary controls or reduced reimbursement rates.
- Manufacturing Issues: Supply chain disruptions or quality control problems could impact market availability and reputation.
Opportunities:
- Expanded Indication Approvals: Successful clinical trials and subsequent approvals for new patient populations or disease states could significantly increase the addressable market.
- Geographic Market Expansion: Entering new international markets with tailored market access strategies.
- Combination Therapies: Development of synergistic treatments where NDC 67877-0704 is used in combination with other agents.
- Lifecycle Management: Development of next-generation formulations or delivery methods that offer improved patient convenience or efficacy, potentially extending market exclusivity.
- Real-World Evidence (RWE) Generation: Robust RWE studies can reinforce the drug's value proposition to payers and physicians, supporting its use and pricing.
Key Takeaways
NDC 67877-0704 is poised for continued revenue generation during its patent-protected period, driven by its clinical profile. The market will undergo a significant transformation upon patent expiry, with substantial price declines and increased competition from generics/biosimilars. Strategic planning for lifecycle management and defense against market erosion is critical.
Frequently Asked Questions
1. When is the earliest a generic version of NDC 67877-0704 could enter the market?
The earliest potential generic entry is contingent on the expiration of the primary composition of matter patent, U.S. Patent No. [Patent Number], which is scheduled for [Expiration Date]. However, generic manufacturers can also challenge secondary patents, potentially leading to earlier market entry if successful.
2. What is the typical price reduction observed for similar drugs upon generic or biosimilar launch?
For small molecule drugs, price reductions upon generic entry typically range from 40% to 85% within two years of the first generic launch, depending on the number of competitors and market dynamics. For biologics, biosimilar price reductions are generally more modest, often in the range of 15% to 35% initially, but can increase with greater market penetration.
3. Are there any ongoing legal challenges that could impact the patent exclusivity of NDC 67877-0704?
[State Yes/No and if Yes, provide brief details. If No, state: As of the latest available public records, there are no significant, publicly disclosed legal challenges that would definitively alter the expected patent exclusivity timeline for NDC 67877-0704.]
4. What is the estimated market size for NDC 67877-0704 in 2028, assuming continued patent protection?
Assuming no generic or biosimilar entry before then and sustained market penetration, the estimated market size for NDC 67877-0704 in 2028 is projected to be approximately $[X.XX] billion.
5. How does the manufacturing cost of NDC 67877-0704 compare to that of potential generic competitors?
The current manufacturing cost for the branded NDC 67877-0704 is estimated at $[X] per [Unit]. Generic manufacturers typically achieve lower production costs through economies of scale, optimized synthesis routes, and less stringent regulatory overhead for manufacturing facilities post-approval. While exact figures for generic competitors are not yet public, their costs are expected to be significantly lower.
Cited Sources
[1] U.S. Patent and Trademark Office. (n.d.). Patent Full-Text and Image Database. Retrieved from [URL of USPTO Patent Database, if specific patent cited directly]
[2] Food and Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from [URL of FDA Drug Approval Database, if specific approval date cited directly]
[3] [Name of Market Research Firm or Industry Report]. (Year). [Title of Report related to the drug or therapeutic class]. [Publisher/Source].
[4] [Name of Financial Analyst Firm or Investment Bank Report, if used]. (Year). [Title of Report on the pharmaceutical company or drug]. [Publisher/Source].
[5] [Name of Healthcare Payer or Policy Analysis Group Report, if used]. (Year). [Title of Report on drug pricing or reimbursement]. [Publisher/Source].
More… ↓
